Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial

Zhou C.Ramalingam S.S.Kim T.M.Kim S.-W.CHIH-HSIN YANGRiely G.J.Mekhail T.Nguyen D.Garcia Campelo M.R.Felip E.Vincent S.Jin S.Griffin C.Bunn V.Lin J.Lin H.M.Mehta M.J?nne P.A.2022-08-102022-08-1020212374-2437https://www.scopus.com/inward/record.uri?eid=2-s2.0-85117253113&doi=10.1001%2fjamaoncol.2021.4761&partnerID=40&md5=0d1ae6d8709b244aa500aa4bf5593423https://scholars.lib.ntu.edu.tw/handle/123456789/616496[SDGs]SDG3Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trialjournal article10.1001/jamaoncol.2021.4761346479882-s2.0-85117253113